BriaCell Therapeutics : NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS - Form 8-K -April 02, 2024 at 04:09 pm EDT

NOTICE OF NO AUDITOR REVIEW OF THE


CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS


In accordance with National Instrument 51-102 Part 4, subsection 4.3, if...

Related Keywords

United Kingdom ,United States ,Vancouver ,British Columbia ,Canada ,Toronto ,Ontario ,British ,Martin Schmieg ,William Williams ,National Instrument ,Company To Briacell ,Services To Briapro ,Toronto Stock Exchange ,Transition Services Agreement ,International Financial Reporting Standards ,Briapro Therapeutics Corp ,Briacell Therapeutics Corp ,International Financial Reporting Interpretations Committee ,International Accounting Standards ,International Accounting Standards Board ,Nasdaq ,Briapro Therapeutics ,Condensed Interim Statements ,Financial Position ,Condensed Interim Statement ,Comprehensive Loss ,Interim Statement ,Cash Flows ,Condensed Interim Financial Statements ,Pro Therapeutics ,Business Corporations Act ,Briapro Assets ,Briacell Shareholders ,Effective Date ,Warrant Share ,Presentation Currency ,Share Purchase ,Briacell Share ,Briapro Share ,Briacell Warrants ,Briacell Warrant ,Pro Rata Warrant ,Cell Warrants ,Balance Sheet ,Briapro Board ,Briapro Option ,Briacell Option ,Pro Option Exercise ,Omnibus Plan ,Share Units ,Transition Agreement ,Markets ,